Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
Sign Up to like & getrecommendations! Published in 2018 at "Molecular Medicine Reports"
DOI: 10.3892/mmr.2018.9347
Abstract: As patients with non-small cell lung cancer (NSCLC) and wild-type epidermal growth factor receptor (EGFR) are resistant to treatment with erlotinib or gefitinib, potential chemosensitizers are required to potentiate wild-type EGFR NSCLC cells to erlotinib/gefitinib… read more here.
Keywords: type egfr; erlotinib gefitinib; egfr nsclc; wild type ... See more keywords